PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.91%
Revenue growth under 50% of CRON.TO's 30.52%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
229.93%
Gross profit growth under 50% of CRON.TO's 3917.80%. Michael Burry would be concerned about a severe competitive disadvantage.
-19.65%
Negative EBIT growth while CRON.TO is at 10.51%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-19.65%
Negative operating income growth while CRON.TO is at 94.91%. Joel Greenblatt would press for urgent turnaround measures.
495.53%
Net income growth under 50% of CRON.TO's 3980.46%. Michael Burry would suspect the firm is falling well behind a key competitor.
479.36%
EPS growth under 50% of CRON.TO's 3964.86%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
486.45%
Diluted EPS growth under 50% of CRON.TO's 1203.68%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-128.34%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-5.43%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
231.50%
3Y revenue/share CAGR under 50% of CRON.TO's 8364.80%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-2712.91%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-106697.14%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-432.17%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
2364.45%
Below 50% of CRON.TO's 8452.66%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
4240.51%
5Y net income/share CAGR at 50-75% of CRON.TO's 8452.66%. Martin Whitman might see a shortfall in operational efficiency or brand power.
1153.04%
Below 50% of CRON.TO's 16291.70%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
5805.96%
10Y equity/share CAGR above 1.5x CRON.TO's 1621.51%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
7110.93%
5Y equity/share CAGR above 1.5x CRON.TO's 1621.51%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
2546.66%
3Y equity/share CAGR above 1.5x CRON.TO's 1537.12%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
515.88%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
55.77%
Inventory growth well above CRON.TO's 81.01%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
22.83%
Asset growth well under 50% of CRON.TO's 954.02%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
23.55%
Under 50% of CRON.TO's 367.51%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
78.69%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
25.44%
R&D growth of 25.44% while CRON.TO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
5.88%
SG&A declining or stable vs. CRON.TO's 35.67%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.